All Names: Rematib,upadacitinib,Rinvoq
Indications:Active Rheumatoid Arthritis
Manufacturer:AbbVie,USA
Customs Clearance Procedure:If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE(适应症)
RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.
DOSAGE(服用剂量)
The recommended oral dose of RINVOQ is 15 mg once daily with or without food.
RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.
ADVERSE REACTIONS(不良反应)
Serious Infections
Malignancy
Thrombosis
Gastrointestinal Perforations
Laboratory Parameters
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/2966aec7-2ef0-923c-d8ff-fe1a957bf095/spl-doc?hl=upadacitinib
Rinvoqinformation
No information yet!!!